Page last updated: 2024-11-12

schisandrol a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

schisandrol A: dibenzocyclooctadiene lignan from Schisandra chinensis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11102092
CHEMBL ID1669433
MeSH IDM0510674

Synonyms (9)

Synonym
AC-20311
schisandrol a
hexamethoxy(dimethyl)[?]ol
CHEMBL1669433
AKOS015965247
(6r,7s)-1,2,3,10,11,12-hexamethoxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c][8]annulen-6-ol
(9r,10s)-3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaen-9-ol
A865915
AC-34829

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" After oral administration of FZHY at a dose of 15g/kg, the pharmacokinetic behaviors of schizandrin A (SIA), schizandrin B (SIB), schizandrin C (SIC), schisandrol A (SOA), Schisandrol B (SOB) and schisantherin A (STA) have been significantly changed in hepatic fibrosis rats compared with the normal rats, and their AUC(0-t) values were increased by 235."( Comparative pharmacokinetics and tissue distribution profiles of lignan components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe.
Liu, CH; Liu, S; Tao, YY; Yang, T; Zheng, TH, 2015
)
0.62
"9 g/kg SY, nifedipine clearance decreased by 34% and half-life increased by 142%."( Shenmai-Yin decreased the clearance of nifedipine in rats: The involvement of time-dependent inhibition of nifedipine oxidation.
Chen, AC; Chen, WC; Lu, CK; Ueng, YF; Wang, HJ, 2019
)
0.51
" The integrated UPLC-Q-TOF/MS, pharmacodynamic study, histopathological combination with network pharmacology and molecular docking technology were used to explore the potential mechanisms."( Network pharmacology, molecular docking technology integrated with pharmacodynamic study to reveal the potential targets of Schisandrol A in drug-induced liver injury by acetaminophen.
Deng, S; Ge, J; Li, J; Li, M; Li, X; Ma, L; Ma, Y; Zhang, J; Zheng, Y, 2022
)
0.93

Bioavailability

ExcerptReferenceRelevance
" It suggested that the potential interactions of SMS with CYP 3A drug substrates should be noticed, especially the drugs whose bioavailability depends heavily on intestinal CYP3A."( Effects of Shengmai San on key enzymes involved in hepatic and intestinal drug metabolism in rats.
Chia-Hui Tan, E; Chiang, TY; Lee, IJ; Ueng, YF; Wang, HJ; Wang, YC; Yun, CH, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" Six lignans pretreatment before APAP dosing could prevent the depletions of total liver glutathione (GSH) and mitochondrial GSH caused by APAP."( Hepato-protective effects of six schisandra lignans on acetaminophen-induced liver injury are partially associated with the inhibition of CYP-mediated bioactivation.
Bi, H; Chen, P; Fan, X; Huang, M; Jiang, Y; Tan, H; Wang, Y; Zeng, H, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1332258Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Biotransformation of isofraxetin-6-O-β-d-glucopyranoside by Angelica sinensis (Oliv.) Diels callus.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (6.06)29.6817
2010's22 (66.67)24.3611
2020's9 (27.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.00 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]